Burlingame CA – 20 May 2026 – Download Press Release
Collaborative Drug Discovery (CDD), the leading provider of data management solutions for the pharmaceutical and biotechnology industries, today announced an agreement with Eli Lilly and Company (Lilly) to integrate Lilly TuneLab, a collaborative AI/ML drug discovery platform, into CDD Vault.
Lilly TuneLab was created by Lilly to accelerate biotech innovation by enabling participating companies to access models trained on decades of Lilly’s proprietary research data. Through this agreement, biotech companies that use CDD Vault will be able…
Welcome to the Q2 Edition of Our People Pathways Newsletter!
This issue is packed with practical opportunities to develop your skills and grow your network. You'll find upcoming training courses covering everything from communication to biological safety, plus a NEW seminar on maximising your cash runway - essential for anyone navigating life science funding. We're also spotlighting our next HR SIG session, mentoring initiative testimonials, and the latest toxicology course from CATS and BTS. And if you're passionate about supporting emerging talent, we have highlighted some student…
BURLINGAME, Calif., May 20, 2026 /PRNewswire/ -- Collaborative Drug Discovery (CDD), the leading provider of data management solutions for the pharmaceutical and biotechnology industries, today announced an agreement with Eli Lilly and Company (Lilly) to integrate Lilly TuneLab, a collaborative AI/ML drug discovery platform, into CDD Vault.
Lilly TuneLab was created by Lilly to accelerate biotech innovation by enabling participating companies to access models trained on decades of Lilly's proprietary research data. Through this agreement, biotech companies that use CDD Vault will be able to…
LONDON, UK, and COPENHAGEN, Denmark – May 14, 2026 – Coulter Partners, the global expert building leadership teams for Health, Science and Technology innovation businesses, successfully led a search for Neumirna Therapeutics (“Neumirna”) and is pleased to announce the placement of Dr. Ferenc Tracik as Chief Medical Officer (CMO). Neumirna Therapeutics is a biotechnology company dedicated to developing RNA-based therapies for complex neurological diseases. Dr. Tracik is a physician-leader with more than two decades of expertise in neurological and rare disease…
MB097 used in combination with MSD’s anti-PD-1 therapy, KEYTRUDA® (pembrolizumab)
Cambridge, UK – 18 May 2026: Microbiotica, a clinical-stage biopharma company developing a pipeline of oral precision microbiome medicines called live biotherapeutic products (LBPs), announces that all primary and secondary objectives were met in its advanced melanoma (MELODY-1) Phase 1b trial.
MELODY-1 was an international Phase 1b study to evaluate the safety and tolerability of MB097 given in combination with KEYTRUDA® (pembrolizumab), MSD’s anti-PD-1 therapy, in patients with advanced melanoma who…
Funding to identify novel targets for ALS treatment using OutSee’s ‘genomics first’ target discovery platform, Nomaly
Provides access to world’s largest and most comprehensive ALS patient dataset
Part of £7.5M global challenge prize to leverage innovations in AI-based discovery
Cambridge, UK, 19 May 2026: OutSee, a genomics and drug discovery company pioneering a unique AI-based predictive genomics approach to target discovery, today announced it has been selected to receive a Discovery Award from the Longitude Prize on ALS. The award grants OutSee access to genomic data from…
Qureight’s AI-powered quantitative imaging analytics platform and services to analyse HRCT images to evaluate changes in compartment-specific lung biomarkers
The focus of these efforts will be on the quantitative assessment of change from baseline in lung fibrosis
Qureight’s imaging models, including Glass8™, Fibr8™, Vascul8™, Air8™ and Lung8™, enable precise compartment-specific assessment of inflammatory, fibrotic, vascular and airway-related changes in the lungs, supporting deeper understanding of disease progression and therapeutic response in Systemic Sclerosis
MTX-474 is a monoclonal…
Amsbio reports how researchers from the Karolinska Institute, Stockholm, Sweden are using their Adeno Associated Virus (AAV) products in a groundbreaking investigation into the causes of Rheumatoid Arthritis pain.
Rheumatoid arthritis (RA) pain is not explained well by inflammation alone. In a new peer reviewed study** the Swedish researchers describe the multitude of approaches they used to uncover the neural basis and causes of the inflammatory pain. In one described methodology the researchers used AAV produced by Amsbio for conditional Ifnar1 knockout in sensory neuron and pharmacological…
o2h Discovery, a leading integrated drug discovery CRO, today announces the launch of the latest edition of o2h Kickstarter Award for Peptide, a dedicated programme/Award designed to support early-stage biotech companies advancing peptide-based therapeutics.
Building on the success of the o2h Kickstarter Award, which has supported more than 40 early-stage biotech companies globally since 2022, o2h Discovery is now expanding its flagship initiative to address the growing demand for peptide drug discovery expertise. The Peptide Kickstarter Award is purpose-built for startups working on peptide-…
AI hallucinations in drug discovery aren't just an AI problem — they're a data problem.
👉 52% of life science professionals say poor data quality is the #1 barrier to AI implementation
👉 27% of organisations can't even trace the evidence chain powering their AI systems.
In this new white-paper authored by Digital Science's Mark Hahnel we see the practical playbook: FAIR data principles, knowledge graphs, and neuro-symbolic AI for building a foundation pharma can actually trust.
If you're navigating AI in R&D and wondering why it isn't delivering, this is for…